SG Americas Securities LLC reduced its stake in Pool Corporation by 10.9% in the first quarter, selling 8,801 shares and now owning 71,919 shares valued at approximately $14.6 million. Despite this, insiders have been buying the stock, with various directors purchasing a total of 21,989 shares worth about $4.0 million in the last three months. Pool Corporation also reported better-than-expected earnings, approved a $600 million share buyback, and increased its quarterly dividend to $1.30 per share.

Erasca, Inc. is facing a securities class action lawsuit after its stock dropped significantly following accusations of patent infringement by Revolution Medicines and the death of a patient receiving its ERAS-0015 treatment. The lawsuit alleges that Erasca misled investors regarding the intellectual property protection and safety of its pan-RAS molecular glue, ERAS-0015, resulting in a $2.8 billion market cap loss. Hagens Berman is investigating the claims and urging affected investors to contact the firm.

RBC Capital has upgraded American Tower (NYSE:AMT) from Sector Perform to Outperform, raising its price target to $205 from $195. The upgrade is attributed to American Tower's superior organic revenue growth and favorable trends at CoreSite, making it RBC's preferred tower company pick. The move comes as American Tower trades near its 52-week low, with analysts expecting strong U.S. net organic tower growth through fiscal year 2026.

Aaron Wealth Advisors LLC reduced its stake in Advanced Micro Devices ($AMD) by 6.3% in the first quarter, holding 15,606 shares valued at $3.18 million. Despite this, Wall Street analysts maintain a "Moderate Buy" rating for AMD with an average price target of $440.41, with some targets as high as $670. The company's recent earnings exceeded expectations, though insider selling has also been noted.

Apella Capital LLC significantly increased its stake in Lockheed Martin Corporation, boosting its holdings by 180.9% to 5,674 shares valued at $3.36 million. This increase comes as Lockheed Martin secured a substantial seven-year, $35 billion government contract for THAAD missiles, signaling long-term revenue growth. Despite the positive contract news and a solid dividend, analysts generally maintain a "Hold" rating for the stock.

CommVault Systems (NASDAQ:CVLT) recently saw its stock price rise above its 200-day moving average, trading at $133.94 after reaching a high of $135.69. This rise is partly attributed to a new multi-year strategic partnership with Microsoft to integrate its AI and cyber-resilience platform into Azure. Despite the positive news, investor sentiment is mixed due to ongoing securities litigation and recent insider stock sales, even as analysts maintain a "Moderate Buy" consensus.

Aflac Dental Insurance provides fixed cash benefits for routine dental care, fillings, and major dental work, with optional vision and hearing riders available in many U.S. states. This supplemental policy pays policyholders a set amount for defined services, independent of the dentist's actual charges, making it an attractive addition to existing health plans. The product is primarily distributed through employers and agents in the U.S. market, aligning with Aflac's strategy to deepen relationships with employers and employees through voluntary benefits.

This article provides an overview of Curis, Inc. (MUN:CUS0) financials, including actual results, analyst estimates, and key financial metrics. It covers income statements, balance sheets, cash flow, and valuation metrics, along with answers to frequently asked questions about its stock performance, earnings, and revenue.

Italy's antitrust authority has launched an investigation into Microsoft Ireland Operations Ltd. and Microsoft due to alleged unfair commercial practices. The probe focuses on a recent price increase for its Microsoft 365 subscription service. The regulator claims that Microsoft failed to adequately inform consumers about this price hike.

Banque Cantonale Vaudoise significantly increased its stake in CVS Health Corporation, purchasing 71.5% more shares in the first quarter. This move aligns with a "Moderate Buy" consensus rating from Wall Street analysts, who have also raised price targets for CVS. The company reported strong first-quarter earnings, surpassing expectations, and maintained its positive FY 2026 EPS guidance.